GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The trial will enroll up to 42 patients in Finland across four cohorts
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Subscribe To Our Newsletter & Stay Updated